WASHINGTON — Researchers have identified a potential biomarker that could aid in diagnosing chronic traumatic encephalopathy (CTE), a degenerative brain disease linked to repeated head trauma. The findings, while preliminary, suggest that a protein fragment commonly associated with Alzheimer’s disease may also be elevated in individuals with advanced stages of CTE.
CTE has primarily been diagnosed postmortem through brain examinations, as its symptoms—such as mood changes and memory loss—overlap with those of other neurological conditions. Scientists at Washington University in St. Louis were investigating a tau protein fragment called eMTBR-tau243, which is known to form tangles inside nerve cells in Alzheimer’s patients. Unexpectedly, they found elevated levels of this biomarker in the brain tissue of a patient diagnosed with advanced CTE but not Alzheimer's disease.
Expanding their research, the team analyzed autopsy samples and stored blood from 11 individuals previously identified with CTE. They observed that levels of eMTBR-tau243 were higher in those with advanced CTE compared to healthy controls. However, the biomarker did not reliably indicate early-stage CTE, highlighting limitations in its current diagnostic potential.
Co-author Chihiro Sato, an assistant professor of neurology at Washington University, described the results as an intriguing hint that warrants further investigation. She noted that abnormal tau proteins, which are implicated in several neurodegenerative diseases, often overlap in older adults, complicating the interpretation of their role in CTE.
Independent experts have urged caution, emphasizing the need for larger and more comprehensive studies to validate the findings. Dr. Rudolph Castellani, a neuropathologist at Northwestern University who was not involved in the research, remarked that while the discovery is interesting, the complexity of tauopathies across various brain disorders requires careful differentiation.
The study's results were published in the journal JAMA and presented at a scientific conference in Japan. Researchers say continued efforts are necessary to develop reliable biomarkers that could allow for earlier and more accurate diagnosis of CTE, potentially improving care and outcomes for affected individuals, including athletes and others who have experienced repeated head injuries.
